GelSana Therapeutics, Inc.
GelSana Therapeutics is a Colorado-based biomaterials company developing innovative, highly elastic wound dressings that conform to any wound, reduce inflammation, prevent infection, and provide sustained drug delivery. Their mission is to revolutionize wound healing, including for chronic wounds, through proprietary polymer chemistry and advanced hydrogel technology.
Industries
Nr. of Employees
small (1-50)
GelSana Therapeutics, Inc.
12635 E Montview Blvd, STE 216, Aurora, CO 80045
Products
Hydrogel wound dressing formulations for chronic and diabetic wounds
Prototype hydrogel dressings engineered to accelerate wound closure, reduce local inflammation, reduce infection risk, and enable sustained topical delivery of therapeutics.
Sustained anti-inflammatory cytokine delivery hydrogel (development project)
Hydrogel formulation under NIH SBIR development intended to deliver anti-inflammatory cytokines in a sustained fashion for treatment of diabetic foot ulcers.
Hydrogel wound dressing formulations for chronic and diabetic wounds
Prototype hydrogel dressings engineered to accelerate wound closure, reduce local inflammation, reduce infection risk, and enable sustained topical delivery of therapeutics.
Sustained anti-inflammatory cytokine delivery hydrogel (development project)
Hydrogel formulation under NIH SBIR development intended to deliver anti-inflammatory cytokines in a sustained fashion for treatment of diabetic foot ulcers.
Services
Collaborative research and preclinical testing partnerships to evaluate hydrogel wound dressing performance in animal models and adapt formulations for specific clinical use cases.
Management and execution of SBIR- and grant-funded development projects focused on sustained delivery hydrogels and military-relevant wound treatments.
Collaborative research and preclinical testing partnerships to evaluate hydrogel wound dressing performance in animal models and adapt formulations for specific clinical use cases.
Management and execution of SBIR- and grant-funded development projects focused on sustained delivery hydrogels and military-relevant wound treatments.
Expertise Areas
- Wound healing biomaterials
- Sustained topical drug delivery
- Zwitterionic polymer chemistry and cryogelation
- Preclinical wound healing studies (diabetic wound models)
Key Technologies
- Zwitterionic hydrogels
- Cryogelation (freeze-polymerized gels)
- Sustained/controlled release formulations
- Topical cytokine and biologic delivery
News & Updates
GelSana pitched at the CLS Innovation Showcase at UC Berkeley in June 2023, meeting investors and entrepreneurs.
Melissa Krebs pitched at the Women in BIO Lobster Pot Pitch Event in June 2023, making connections in the biotech community.
GelSana was chosen as a cohort company for the California Life Sciences FAST program to build business and commercialization goals.
Selected to participate and win the TechConnect World Innovation Conference 2022 Medical Innovation Challenge in Baltimore.
Received NIH SBIR Phase I funding through NIDDK for a hydrogel for sustained delivery of anti-inflammatory cytokines to treat diabetic foot ulcers.
Melissa Krebs, CEO of GelSana, discusses the underfunding of women-led startups and her company's innovative hydrogel for wound healing.
GelSana pitched at the CLS Innovation Showcase at UC Berkeley in June 2023, meeting investors and entrepreneurs.
Melissa Krebs pitched at the Women in BIO Lobster Pot Pitch Event in June 2023, making connections in the biotech community.
GelSana was chosen as a cohort company for the California Life Sciences FAST program to build business and commercialization goals.
Selected to participate and win the TechConnect World Innovation Conference 2022 Medical Innovation Challenge in Baltimore.
Received NIH SBIR Phase I funding through NIDDK for a hydrogel for sustained delivery of anti-inflammatory cytokines to treat diabetic foot ulcers.
Melissa Krebs, CEO of GelSana, discusses the underfunding of women-led startups and her company's innovative hydrogel for wound healing.